ECSP22049008A - M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina - Google Patents

M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina

Info

Publication number
ECSP22049008A
ECSP22049008A ECSENADI202249008A ECDI202249008A ECSP22049008A EC SP22049008 A ECSP22049008 A EC SP22049008A EC SENADI202249008 A ECSENADI202249008 A EC SENADI202249008A EC DI202249008 A ECDI202249008 A EC DI202249008A EC SP22049008 A ECSP22049008 A EC SP22049008A
Authority
EC
Ecuador
Prior art keywords
lurbinectedin
methods
formulations
treatment
lung cancer
Prior art date
Application number
ECSENADI202249008A
Other languages
English (en)
Inventor
Pilar Lardelli
Salvador Fudio
Alba Maria Del Mar Zarzuelo
Jos? Mar?A Fernandez
Maria Tobio
Carmen Kahatt
L?Pez Sonia Manzanaro
Arturo Soto
Cristian Fernandez
Noain Mar?A De La Concepci?N Polanco
Pilar Calvo
Honorio Velasco
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2020/063734 external-priority patent/WO2021228414A1/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of ECSP22049008A publication Critical patent/ECSP22049008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan m?todos para el tratamiento de pacientes con CPCP mediante la administraci?n de cantidades terap?uticas de lurbinectedina mediante infusi?n intravenosa. Tambi?n se proporcionan m?todos para tratar el c?ncer mediante la administraci?n de lurbinectedina en combinaci?n con otros f?rmacos anticancerosos, en particular inhibidores de la topoisomerasa. La invenci?n tambi?n se refiere a la administraci?n de lurbinectedina en combinaci?n con agentes antiem?ticos para el control eficaz de los s?ntomas relacionados con n?useas y v?mitos, dosis reducidas de lurbinectedina para lograr una administraci?n m?s segura y un aumento en el n?mero de ciclos de tratamiento. Tambi?n se proporcionan formulaciones liofilizadas estables de lurbinectedina.
ECSENADI202249008A 2019-11-21 2022-06-20 M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina ECSP22049008A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19383025 2019-11-21
EP20382409 2020-05-14
PCT/EP2020/063734 WO2021228414A1 (en) 2020-05-14 2020-05-15 Methods of treating small cell lung cancer with lurbinectedin formulations
PCT/EP2020/065093 WO2021098992A1 (en) 2019-11-21 2020-05-29 Methods of treating small cell lung cancer with lurbinectedin formulations

Publications (1)

Publication Number Publication Date
ECSP22049008A true ECSP22049008A (es) 2022-08-31

Family

ID=70918456

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249008A ECSP22049008A (es) 2019-11-21 2022-06-20 M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina

Country Status (17)

Country Link
US (6) US20230027502A1 (es)
EP (1) EP4061372A1 (es)
JP (1) JP2023503318A (es)
KR (1) KR20220119618A (es)
CN (1) CN115151259A (es)
AU (1) AU2020388196A1 (es)
BR (1) BR112022009283A2 (es)
CA (1) CA3158733A1 (es)
CL (1) CL2022001342A1 (es)
CO (1) CO2022008437A2 (es)
CR (1) CR20220289A (es)
EC (1) ECSP22049008A (es)
IL (1) IL293128A (es)
JO (1) JOP20220118A1 (es)
MX (1) MX2022006208A (es)
PE (1) PE20221338A1 (es)
WO (1) WO2021098992A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079177A1 (en) * 2021-11-08 2023-05-11 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
WO2005077341A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
JP6037337B2 (ja) * 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
BR122017028570B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um inibidor da topoisomerase i e/ou ii e kit
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Also Published As

Publication number Publication date
CO2022008437A2 (es) 2022-07-29
US20230390286A1 (en) 2023-12-07
MX2022006208A (es) 2022-07-05
KR20220119618A (ko) 2022-08-30
BR112022009283A2 (pt) 2022-08-02
WO2021098992A1 (en) 2021-05-27
PE20221338A1 (es) 2022-09-13
CL2022001342A1 (es) 2023-03-17
US20230390285A1 (en) 2023-12-07
US20240041872A1 (en) 2024-02-08
EP4061372A1 (en) 2022-09-28
US20230027502A1 (en) 2023-01-26
US20240041874A1 (en) 2024-02-08
CA3158733A1 (en) 2021-05-27
JOP20220118A1 (ar) 2023-01-30
IL293128A (en) 2022-07-01
CR20220289A (es) 2022-10-27
US20240041873A1 (en) 2024-02-08
CN115151259A (zh) 2022-10-04
JP2023503318A (ja) 2023-01-27
AU2020388196A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
ECSP22049008A (es) M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina
RU2747124C2 (ru) Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
ECSP109969A (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MA56827B2 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2012131811A5 (es)
WO2014160216A3 (en) Dual targeting anticancer agents
CL2018002734A1 (es) Métodos de tratamiento con vitamina d
JP2016515586A5 (es)
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
BR112022009798A2 (pt) Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
WO2014145199A3 (en) Retrograde delivery of sdf-1 for treatment of myocardial infarction